Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

MDMA-Assisted Therapy for Post-Traumatic Stress Disorder: Regulatory Challenges and a Path Forward

CNS Drugs(2025)10.1007/s40263-025-01162-ySource: DataRank Database

MDMA-Assisted Therapy for Post-Traumatic Stress Disorder: Regulatory Challenges and a Path Forward is a research paper published in CNS Drugs (2025). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 9.12)OA: greenTopics (88)IDs (PubMed, PMC, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (1)

Balwinder Singh ORCID

Live enrichment

PubMed:39955464 PMC:PMC11910333 OpenAlex:https://openalex.org/W4407595168

National Center for Advancing Translational Sciences

Grant: KL2 TR002379

National Institutes of Health

Grant: 5KL2TR002379-09

Institutional Career Development Core

FWCI

9.12

Citation Percentile

1.0%

Citation Trend

2025

2026

greenLicense: Springer Nature TDM

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11910333/pdf/nihms-2058386.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s40263-025-01162-y.pdf

publisherhttps://link.springer.com/article/10.1007/s40263-025-01162-y/fulltext.html

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11910333/

Fields of Study

Psychedelics and Drug StudiesCannabis and Cannabinoid ResearchChemical synthesis and alkaloids03 medical and health sciences0305 other medical scienceAdultAgedFemaleHumansMaleMiddle AgedYoung AdultClinical Trials, Phase III as TopicDrug ApprovalDrug Therapy, CombinationHallucinogensN-Methyl-3,4-methylenedioxyamphetaminePrevalencePsychotherapyRandomized Controlled Trials as TopicResearch DesignRisk FactorsSelective Serotonin Reuptake InhibitorsSex FactorsStress Disorders, Post-TraumaticTreatment OutcomeUnited StatesUnited States Food and Drug AdministrationVeterans

MeSH Terms

AdultAgedDrug Therapy, CombinationFemaleHallucinogensHumansMaleMiddle AgedPsychotherapyResearch DesignRisk FactorsSex FactorsStress Disorders, Post-TraumaticUnited StatesUnited States Food and Drug AdministrationVeteransPrevalenceRandomized Controlled Trials as TopicTreatment OutcomeDrug ApprovalClinical Trials, Phase III as TopicSelective Serotonin Reuptake InhibitorsN-Methyl-3,4-methylenedioxyamphetamineYoung Adult

Keywords

MDMASertralinePsychiatryMedicineTraumatic stressFluvoxamineMoodParoxetinePsychologyClinical psychologyAntidepressantFluoxetineAnxietyInternal medicineAdultMaleN-Methyl-3,4-methylenedioxyamphetamineMiddle AgedArticlePsychotherapyStress Disorders, Post-TraumaticYoung AdultSex FactorsClinical Trials, Phase III as TopicResearch DesignRisk FactorsHallucinogensPrevalenceHumansFemaleDrug Therapy, CombinationDrug ApprovalSelective Serotonin Reuptake InhibitorsAgedRandomized Controlled Trials as Topic